Qatar's Sidra Medicine first in region to successfully perform Intraventricular Baclofen Therapy

Innovative neurosurgical treatment offers new hope for patients with severe movement disorders Doha, Qatar: Sidra Medicine, a member of Qatar Found...

Innovative neurosurgical treatment offers new hope for patients with severe movement disorders

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, is the first hospital in the Middle East to successfully perform two Intraventricular Baclofen Therapies. The milestone highlights Sidra Medicine’s commitment to pioneering advanced neurosurgical treatments for children and young people with severe movement disorders.

The procedure was performed on two young people with Dystonia. Dystonia is a neurological condition that causes uncontrolled muscle contractions. Following the procedure at Sidra Medicine, both adolescents experienced a remarkable improvement in their condition, demonstrating the effectiveness of this innovative therapy.

Dr. Ian Pople, Chief of Neurosurgery at Sidra Medicine, who led the procedure and emphasized its significance said: “The neurosurgery performed on both patients was highly successful. Unlike traditional intrathecal Baclofen therapy, which delivers the drug into the spinal fluid via a pump in the lower back, the intraventricular approach administers the medication directly into the brain’s ventricles, allowing for more effective treatment of severe dystonia affecting the entire body. This approach underscores the importance of integrating neurosurgical precision with rehabilitation, ensuring patients receive the most advanced care available.”

Innovative treatment approach